Poland· PL-100504717
Ordspono
A medicinal product containing odronextamab, registered in Poland by Regeneron Ireland Designated Activity Company (DAC).
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Odronextamab
- Manufacturer
- Regeneron Ireland Designated Activity Company (DAC)
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Odronextamab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOrdspono 2 mgRegeneron Ireland Designated Activity Company (DAC)
- CzechiaORDSPONORegeneron Ireland Designated Activity Company, Dublin
- FinlandOrdsponoRegeneron Ireland Designated Activity Company (DAC)
- IrelandOrdspono 2 mg Concentrate for solution for infusionRegeneron Ireland Designated Activity Company
- IcelandOrdsponoRegeneron Ireland Designated Activity Company
- SwedenOrdspono 2 mg Koncentrat till infusionsvätska, lösningRegeneron Ireland Designated Activity Company
- SpainORDSPONO 2 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRegeneron Ireland Designated Activity Company
- NetherlandsOrdspono 2 mg concentraat voor oplossing voor infusieRegeneron Ireland Designated Activity Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ordspono
- Liechtenstein · Ordspono
- Norway · Ordspono
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf63ce7a-a0ee-4be5-aa0c-0735f3314859 GET /v1/drugs/bf63ce7a-a0ee-4be5-aa0c-0735f3314859?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "2 mg",
"packaging": "Rpz ¦ EU/1/24/1843/001 ¦ 157838\n1 fiol.",
"substance": "Odronextamab 2 mg",
"common_name": "Odronextamab",
"pl_product_id": "100504717",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about odronextamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.